ARQULE Stock Quote

$1.545 arrow  Change: 0.12 %Chge: 8.42% Vol: 6,244
End Of Day Prices
High: 1.545 | Low: 1.42 | Open: 1.43 | Close: 1.545
52 Wk High: 1.68 | 52 Wk Low: 0.9399 | Todays Pivot: 1.50
Sector: add stock to watch list

ARQL Chart


You need Flash Player to see the chart, please download from the link below

Get Adobe Flash player

Online News For Arqule

Energy Opportunities Capital Management Has Trimmed Helix Energy Solu Grp Com (HLX) Holding; Profile of 1 Analysts Covering ArQule, Inc. (ARQL)

Energy Opportunities Capital Management Llc decreased Helix Energy Solu Grp Com (HLX) stake by 52.52% reported in 2017Q2 SEC filing. Energy Opportunities Capital Management Llc sold 420,491 shares as Helix Energy Solu Grp Com (HLX)’s stock declined 19.97%.


BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor (ARQL)

* Arqule Inc - ‍trial is being conducted with a biomarker assay to identify fgfr2 fusions Source text for Eikon: Further company coverage:


ArQule Announces Dosing In Registrational Trial Of FGFR Inhibitor Derazantinib

(RTTNews.com) - ArQule, Inc. ( ARQL) on Tuesday announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib or ARQ 087 in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma or iCCA. The trial is ...


ArQule Announces Dosing In A Registrational Trial Of FGFR Inhibitor, Derazantinib, For Treatment Of Intrahepatic Cholangiocarcinoma

ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma (iCCA). The trial is planned to enroll ...


ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocar...

The trial is being conducted with a biomarker assay to identify FGFR2 fusions ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second ...



Want To Add This Quote To Your Site?

With our stock widgets you can add a Arqule quote to your website to keep your users up to date with the market. We have a variety of different styled widgets for ARQL to choose from. Visit here to build your stock quote widget »